415 related articles for article (PubMed ID: 17167821)
1. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
[TBL] [Abstract][Full Text] [Related]
4. CCR2 expression correlates with prostate cancer progression.
Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
[TBL] [Abstract][Full Text] [Related]
5. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines.
Dizeyi N; Bjartell A; Nilsson E; Hansson J; Gadaleanu V; Cross N; Abrahamsson PA
Prostate; 2004 May; 59(3):328-36. PubMed ID: 15042609
[TBL] [Abstract][Full Text] [Related]
6. The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer.
Chang GT; Jhamai M; van Weerden WM; Jenster G; Brinkmann AO
Endocr Relat Cancer; 2004 Dec; 11(4):815-22. PubMed ID: 15613454
[TBL] [Abstract][Full Text] [Related]
7. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
[TBL] [Abstract][Full Text] [Related]
9. [Expression of PIAS3 an inhibitor of activated STAT3 protein in human prostate cancer].
Gan L; Yin ZF; Li M
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):419-21. PubMed ID: 18581899
[TBL] [Abstract][Full Text] [Related]
10. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
11. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
12. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
Freedland SJ; Seligson DB; Liu AY; Pantuck AJ; Paik SH; Horvath S; Wieder JA; Zisman A; Nguyen D; Tso CL; Palotie AV; Belldegrun AS
Prostate; 2003 Apr; 55(1):71-80. PubMed ID: 12640663
[TBL] [Abstract][Full Text] [Related]
13. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
14. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.
Ishiguro H; Nakaigawa N; Miyoshi Y; Fujinami K; Kubota Y; Uemura H
Prostate; 2005 Jun; 64(1):92-100. PubMed ID: 15666359
[TBL] [Abstract][Full Text] [Related]
15. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells.
Grzmil M; Voigt S; Thelen P; Hemmerlein B; Helmke K; Burfeind P
Int J Oncol; 2004 Jan; 24(1):97-105. PubMed ID: 14654946
[TBL] [Abstract][Full Text] [Related]
16. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
[TBL] [Abstract][Full Text] [Related]
17. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
18. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.
Rossi S; Graner E; Febbo P; Weinstein L; Bhattacharya N; Onody T; Bubley G; Balk S; Loda M
Mol Cancer Res; 2003 Aug; 1(10):707-15. PubMed ID: 12939396
[TBL] [Abstract][Full Text] [Related]
20. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
